Anti-obesity drugs and neural circuits of feeding

被引:80
作者
Adan, Roger A. H. [1 ]
Vanderschuren, Louk J. M. J. [1 ]
la Fleur, Susanne E. [1 ]
机构
[1] UMC Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurosci & Pharmacol, NL-3584 CG Utrecht, Netherlands
关键词
D O I
10.1016/j.tips.2008.01.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Most of the drugs that have entered the market for treating obesity were originally developed to treat psychiatric diseases. During the past decade, understanding of the neural circuits that underlie food intake has increased considerably. Different aspects of ingestive behavior such as meal termination, meal initiation and overconsumption of highly rewarding and palatable foods are modulated by different neuroanatomical structures. Integration of the action of many signaling molecules (e.g. hormones, neurotransmitters and neuropeptides) in these structures results in a response that, ultimately, modulates food intake. Thus, the type of drug required by an obese patient might depend on the individual cause of obesity. In this article, we summarize the neural circuits that regulate food intake and we provide a framework for understanding how obesity drugs function. Several potential drug targets are expressed in different neural circuits, implying that current and future obesity drugs act on partially overlapping systems that control food intake.
引用
收藏
页码:208 / 217
页数:10
相关论文
共 123 条
  • [31] Leptin-regulated endocannabinoids are involved in maintaining food intake
    Di Marzo, V
    Goparaju, SK
    Wang, L
    Liu, J
    Bátkai, S
    Járai, Z
    Fezza, F
    Miura, GI
    Palmiter, RD
    Sugiura, T
    Kunos, G
    [J]. NATURE, 2001, 410 (6830) : 822 - 825
  • [32] WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity
    Dunlop, J
    Sabb, AL
    Mazandarani, H
    Zhang, J
    Kalgaonker, S
    Shukhina, E
    Sukoff, S
    Vogel, RL
    Stack, G
    Schechter, L
    Harrison, BL
    Rosenzweig-Lipson, S
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (02) : 862 - 869
  • [33] Leptin activates neurons in ventrobasal hypothalamus and brainstem
    Elmquist, JK
    Ahima, RS
    MaratosFlier, E
    Flier, JS
    Safer, CB
    [J]. ENDOCRINOLOGY, 1997, 138 (02) : 839 - 842
  • [34] Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss
    Erondu, Nogzi
    Wadden, Thomas
    Gantz, Ira
    Musser, Bret
    Nguyen, Allison Martin
    Bays, Harold
    Bray, George
    O'Neil, Patrick M.
    Basdevant, Arnaud
    Kaufman, Keith D.
    Heymsfield, Steven B.
    Amatruda, John M.
    [J]. OBESITY, 2007, 15 (04) : 895 - 905
  • [35] Histamine H3 receptor antagonists:: Preclinical promise for treating obesity and cognitive disorders
    Esbenshade, TA
    Fox, GB
    Cowart, MD
    [J]. MOLECULAR INTERVENTIONS, 2006, 6 (02) : 77 - 88
  • [36] Genetic factors in human obesity
    Farooqi, I. S.
    O'Rahilly, S.
    [J]. OBESITY REVIEWS, 2007, 8 : 37 - 40
  • [37] Leptin regulates striatal regions and human eating Behavior
    Farooqi, I. Sadaf
    Bullmore, Edward T.
    Keogh, Julia
    Gillard, Jonathan
    O'Rahilly, Stephen
    Fletcher, Paul C.
    [J]. SCIENCE, 2007, 317 (5843) : 1355 - 1355
  • [38] Hyperphagic effects of brainstem ghrelin administration
    Faulconbridge, LF
    Cummings, DE
    Kaplan, JM
    Grill, HJ
    [J]. DIABETES, 2003, 52 (09) : 2260 - 2265
  • [39] COMPARATIVE EFFECTIVENESS OF PHENYLPROPANOLAMINE AND DEXTRO AMPHETAMINE ON WEIGHT REDUCTION
    FAZEKAS, JF
    EHRMANTRAUT, WR
    CAMPBELL, KD
    NEGRON, MC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1959, 170 (09): : 1018 - 1021
  • [40] FELDBERG W, 1953, J PHYSIOL-LONDON, V119, P352, DOI 10.1113/jphysiol.1953.sp004850